CD14 AND OTHER LPS RECEPTORS AND ENDOTOXIN SHOCK

CD14 和其他 LPS 受体与内毒素休克

基本信息

  • 批准号:
    2390303
  • 负责人:
  • 金额:
    $ 44.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1989
  • 资助国家:
    美国
  • 起止时间:
    1989-01-01 至 2000-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Adapted from applicant's abstract): The ability to reproduce endotoxin shock in mice provides a unique opportunity to study the biology of the disease and its consequences. The studies proposed here take advantage of the ease of doing experiments in mice and the newest genetic technology. Dr. Goyert has recently produced mice in which the CD14 gene has been disrupted by homologous recombination. These mice provide a unique opportunity to ask several fundamental questions about the nature of endotoxin shock, particularly as regards CD14- dependent and CD14-independent pathways to endotoxin shock. In addition, this animal model will allow Dr. Goyert to evaluate the relative contribution of endothelial cell responses to sCD14- LPS complexes in endotoxin shock.This is the first time that such a model has been established for delineating the effects of these three mechanisms. She will also continue development of a new animal model that will respond to endotoxin in a CD14-dependent manner through the human CD14 protein. This model will be used to evaluate the efficacy of reagents (anti-human CD14 mAb, recombinant soluble human CD14) on the endotoxin response of mice expressing a human CD14 gene and lacking expression of the murine CD14 gene. The following questions will be addressed: 1. How does the lack of CD14 affect the response of CD14-knockout mice to LPS, Gram-negative bacteria, Gram-positive bacteria, and complexes of LPS and soluble CD14? 2. How effective are soluble human CD14 and anti-human CD14 mAb in preventing endotoxin shock in mice expressing human but not murine CD14? Furthermore, can efficacious, unique CD14-specific mAbs be generated in CD14-deficient mice? 3. What is the three-dimensional structure of CD14? 4. What is the nature of the endothelial cell receptor for the complex of LPS-soluble CD14 and is it present on other cell types that also respond to this complex?
描述(摘自申请人摘要):具有复制能力

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sanna M Goyert其他文献

CD14 Downregulate the TNF-α Response, but Plays No Major Role in Shock Induced by Group B Streptococcus Infection
CD14 下调肿瘤坏死因子-α反应,但在 B 组链球菌感染引起的休克中不起主要作用
  • DOI:
    10.1203/00006450-199904020-01591
  • 发表时间:
    1999-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Lourdes Cohen;Sophie C Gangloff;Alain Haziot;Giuseppe Teti;Sanna M Goyert
  • 通讯作者:
    Sanna M Goyert

Sanna M Goyert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sanna M Goyert', 18)}}的其他基金

CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
急性期 LPS 受体的特征
  • 批准号:
    6386492
  • 财政年份:
    2000
  • 资助金额:
    $ 44.52万
  • 项目类别:
CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
急性期 LPS 受体的特征
  • 批准号:
    6194383
  • 财政年份:
    2000
  • 资助金额:
    $ 44.52万
  • 项目类别:
CHARACTERIZATION OF THE LPS RECEPTOR FOR ACUTE PHASE
急性期 LPS 受体的特征
  • 批准号:
    6520033
  • 财政年份:
    2000
  • 资助金额:
    $ 44.52万
  • 项目类别:
MOLECULAR ANALYSIS OF MACROPHAGE ACTIVATION VIA LBP--LPS
LBP--LPS 激活巨噬细胞的分子分析
  • 批准号:
    2184577
  • 财政年份:
    1992
  • 资助金额:
    $ 44.52万
  • 项目类别:
MOLECULAR ANALYSIS OF MACROPHAGE ACTIVATION VIA LBP:LPS
通过 LBP:LPS 激活巨噬细胞的分子分析
  • 批准号:
    3306655
  • 财政年份:
    1992
  • 资助金额:
    $ 44.52万
  • 项目类别:
MOLECULAR ANALYSIS OF MACROPHAGE ACTIVATION VIA LBP:LPS
通过 LBP:LPS 激活巨噬细胞的分子分析
  • 批准号:
    3306656
  • 财政年份:
    1992
  • 资助金额:
    $ 44.52万
  • 项目类别:
CD14 AND OTHER LPS RECEPTORS AND ENDOTOXIN SHOCK
CD14 和其他 LPS 受体与内毒素休克
  • 批准号:
    2062363
  • 财政年份:
    1989
  • 资助金额:
    $ 44.52万
  • 项目类别:
CD14 AND OTHER LPS RECEPTORS AND ENDOTOXIN SHOCK
CD14 和其他 LPS 受体与内毒素休克
  • 批准号:
    2671871
  • 财政年份:
    1989
  • 资助金额:
    $ 44.52万
  • 项目类别:
ROLE OF CD14 AND OTHER LPS RECEPTORS IN ENDOTOXIC SHOCK
CD14 和其他 LPS 受体在内毒素休克中的作用
  • 批准号:
    6693442
  • 财政年份:
    1989
  • 资助金额:
    $ 44.52万
  • 项目类别:
ROLE OF CD14 AND OTHER LPS RECEPTORS IN ENDOTOXIC SHOCK
CD14 和其他 LPS 受体在内毒素休克中的作用
  • 批准号:
    7315275
  • 财政年份:
    1989
  • 资助金额:
    $ 44.52万
  • 项目类别:

相似海外基金

Development of back bone vectors for chimeric antigen receptors against key molecules, CD47 and CD24, activating macrophages
开发针对关键分子 CD47 和 CD24 的嵌合抗原受体的骨干载体,激活巨噬细胞
  • 批准号:
    23K06728
  • 财政年份:
    2023
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CAREER: Engineering next-generation chimeric antigen receptors for cancer immunotherapy using phospho-proteomics
职业:利用磷酸蛋白质组学设计用于癌症免疫治疗的下一代嵌合抗原受体
  • 批准号:
    2145853
  • 财政年份:
    2022
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Continuing Grant
Construction of a drug discovery platform utilizing antigen receptors that regulate the quality of cancer immunity
利用调节癌症免疫质量的抗原受体构建药物发现平台
  • 批准号:
    22K06603
  • 财政年份:
    2022
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Engineering synthetic adhesion receptors to enhance the sensitivity of therapeutic chimeric antigen receptors
工程合成粘附受体以增强治疗性嵌合抗原受体的敏感性
  • 批准号:
    MR/W031353/1
  • 财政年份:
    2022
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Research Grant
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10701754
  • 财政年份:
    2022
  • 资助金额:
    $ 44.52万
  • 项目类别:
Modeling based design of chimeric antigen receptors for Natural Killer cell-based immunotherapy
用于基于自然杀伤细胞的免疫治疗的嵌合抗原受体的基于建模的设计
  • 批准号:
    10557760
  • 财政年份:
    2022
  • 资助金额:
    $ 44.52万
  • 项目类别:
Chimeric antigen receptors on regulatory T cells as a treatment strategy in auto-immune diseases.
调节性 T 细胞上的嵌合抗原受体作为自身免疫性疾病的治疗策略。
  • 批准号:
    437200
  • 财政年份:
    2020
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Studentship Programs
Molecualr imaging for development of chimeric antigen receptors (CARs) resistant to T cell exhaustion
用于开发抗 T 细胞耗竭的嵌合抗原受体 (CAR) 的分子成像
  • 批准号:
    20H03536
  • 财政年份:
    2020
  • 资助金额:
    $ 44.52万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    10542442
  • 财政年份:
    2020
  • 资助金额:
    $ 44.52万
  • 项目类别:
Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell Delivery
通过干细胞递送治疗性抗 HIV 嵌合抗原受体
  • 批准号:
    9922602
  • 财政年份:
    2020
  • 资助金额:
    $ 44.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了